Interviews
Voices from the command deck.
Guided by a great sense of purpose and responsibility, our leaders have a clear vision of corporate values and act accordingly with great integrity.
They perfectly combine strengths to motivate employees and teams to undertake courageous missions, to achieve higher performance by holding them accountable for results. Let’s go deeper by listening to their thoughts and actions through their direct voices.
Interviews
Mirco Montella
Chief Innovation Officer and Deputy Commercial Officer
In addition to the function of Deputy Commercial Officer, Mirco Montella took on the role of Chief Innovation Officer (CIO) to ensure a strong and propulsive push for Innovation.
He leads an interdisciplinary team, capable of proposing solutions by anticipating the evolution of medical technologies and therapies, which will guide Sintetica's entire scientific and industrial innovation process, as well as its commercial and business strategies. Mirco's experience, dynamism and knowledge will be essential qualities to give impetus and incisiveness to a sector that is crucial to Sintetica's identity and corporate culture.
-
We will do it in the same ways that Sintetica has always been distinguished for and that have built its success story: combining the solidity of the tradition made of quality and reliability, attention and listening to the needs of patients and HCP and intelligence and capacity for continuous innovation.
We engage with customers and clinicians to understand unmet needs. We think outside the box, challenge the status quo and accelerate the adoption of new solutions to improve therapies and make an impact.
We are always looking for solutions that make therapies safer, easier to use, and better for patients and practitioners. With a network of partners who share our “quality first” value, we will be able to maintain and expand our current innovation-driven value proposition significantly over next years.
-
Because science is knowledge made up of research, study, discovery, observation, attention and the courage of continuous questioning. Without science there is only improvisation or empiricism. True innovation must be able to develop along these axes. Otherwise it's a leap in the dark. Very dangerous in our field.
The market in which we have specialized and have built our reputation is a rather stable market for what concerns the discovery of new molecules; the ability to increase therapeutic efficiency by moving in a stable context enhances this ability to be innovative. This way of experiencing innovation will allow us to reach the patients and the market through our products, following lasting trends in patient care and grounded in clinicians’ needs.
-
The Innovation Cluster is our most recent creation which has been strongly desired by our CEO and materializes what has been said before in a symbolic way: we have put the intelligence of strategic sectors such as research and development, industrial development, pharmaceutical research and marketing into close interaction to create a virtuous vortex from which the innovations of Sintetica's near future will emerge.
-
Because science is not just theory. Science needs applications and without engineering very often even the most extraordinary innovations would remain only in their state of power. This is an opportunity to explore new avenues for therapies and novel therapeutic areas in which our scientific and industrial capabilities can be applied to solve significant unmet clinical needs.
The technological development speed is impressive and sometimes in the pharmaceutical industry we struggle to follow this, due to the stringent regulations we have abided by. This fact calls on us the importance of thinking broadly when considering new developments and projects. While recognizing the importance of innovation, we constantly invest in the latest technologies and employee training to support scientific and industrial processes and quickly respond to the latest medical discoveries and market requests. This will allow us to reach the markets and patients by following, but also anticipating, the evolution of medical technologies and therapies.
-
There have been huge developments in the technologies used to provide care in the hospital setting over the last two decades. As such, we have developed a strategic product line called Premix which consists of ready to use products in optimized containers that closely meet the needs and capabilities of these technologies. I see there is still huge potential to leverage on our capabilities to make pharmaceuticals available in a Ready-to-use format, cleared by potential harmful preservatives, in different therapeutic areas.
Moreover, there has been a dramatic change in the way surgery is done, with minimally invasive techniques drastically reducing the length of many surgical procedures. We work to develop a scope of innovative products and techniques around this concept to increase our offer in innovative anesthesia.
Lastly, I see our “Pain Science” line of business as focus on developing analgesics with innovative administration solutions and few side-effects. I think there is still room for significant improvement in the way that acute post-surgical pain is managed.
Interviews
Sameer Agarwal
Board Member & Chief Commercial Officer
After several years in the Board of Directors of Sintetica, Sameer Agarwal has additionally taken the responsibility of Chief Commercial Officer bringing with him a deep experience in the pharmaceutical sector. In this interview he shares his reflections on Sintetica’s commercial potential and Sintetica’s strong culture and innovative orientation that keep patients’ needs at the centre.
-
The company started its operations with the aim of meeting the specific needs of patients in Switzerland. This zeal of providing value-added and quality products focused on specific needs is now the core of Sintetica’s global vision. While growing over the years, Sintetica’s other outstanding highlight has been to always stuck to its DNA: a collaborative and innovative functioning of the company.
-
One of the key strategies that Sintetica has always believed in is to remain focused on the two areas of anaesthesia and critical care. This strategy has proved successful and has allowed the company to invest in technological innovation, containers as well as new formulations for treating critically ill patients.
Another key strategy has been covering all major global markets through a combination of Sintetica’s teams and alliance partners. This has enabled Sintetica to bring key products to those who need in a faster and more efficient way.
-
As mentioned earlier, the majority of Sintetica’s portfolio revolves around anaesthesia and critical care products, especially sympathomimetic agents. The company has developed some key intrathecal injectable formulations. With respect to containers, Sintetica specializes in bags, vials and ampoules. While all these product types are likely to continue to grow, I believe that the “ready to use” feature of the bags will help increase the business of Sintetica.
-
The DNA of Sintetica is the collaborative functioning of the company. This has helped tremendously to simultaneously run multiple cross-functional and international complex projects. Regular focused interactions of project teams, often via online platforms, have helped enormously in managing many time-sensitive initiatives.
-
While Sintetica’s outstanding team continues internal brainstorming, it is always keen to listen to the needs of patients, directly from patients as well as healthcare professionals. The company spends substantial resources and time in participating in key international conferences and interacting with key opinion leaders. Sintetica also regularly seeks feedback from its alliance partners, hospitals and clinics to understand patients’ needs.